Skip to main content
Top
Published in: Diabetologia 11/2016

01-11-2016 | Article

The type 2 diabetes presumed causal variant within TCF7L2 resides in an element that controls the expression of ACSL5

Authors: Qianghua Xia, Alessandra Chesi, Elisabetta Manduchi, Brian T. Johnston, Sumei Lu, Michelle E. Leonard, Ursula W. Parlin, Eric F. Rappaport, Peng Huang, Andrew D. Wells, Gerd A. Blobel, Matthew E. Johnson, Struan F. A. Grant

Published in: Diabetologia | Issue 11/2016

Login to get access

Abstract

Aims/hypothesis

One of the most strongly associated type 2 diabetes loci reported to date resides within the TCF7L2 gene. Previous studies point to the T allele of rs7903146 in intron 3 as the causal variant at this locus. We aimed to identify the actual gene(s) under the influence of this variant.

Methods

Using clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein-9 nuclease, we generated a 1.4 kb deletion of the genomic region harbouring rs7903146 in the HCT116 cell line, followed by global gene expression analysis. We then carried out a combination of circularised chromosome conformation capture (4C) and Capture C in cell lines, HCT116 and NCM460 in order to ascertain which promoters of these perturbed genes made consistent physical contact with this genomic region.

Results

We observed 99 genes with significant differential expression (false discovery rate [FDR] cut-off:10%) and an effect size of at least twofold. The subsequent promoter contact analyses revealed just one gene, ACSL5, which resides in the same topologically associating domain as TCF7L2. The generation of additional, smaller deletions (66 bp and 104 bp) comprising rs7903146 showed consistently reduced ACSL5 mRNA levels across all three deletions of up to 30-fold, with commensurate loss of acyl-CoA synthetase long-chain family member 5 (ACSL5) protein. Notably, the deletion of this single-nucleotide polymorphism region abolished significantly detectable chromatin contacts with the ACSL5 promoter. We went on to confirm that contacts between rs7903146 and the ACSL5 promoter regions were conserved in human colon tissue. ACSL5 encodes ACSL5, an enzyme with known roles in fatty acid metabolism.

Conclusions/interpretation

This ‘variant to gene mapping’ effort implicates the genomic location harbouring rs7903146 as a regulatory region for ACSL5.
Appendix
Available only for authorised users
Literature
1.
3.
go back to reference Grant SF, Thorleifsson G, Reynisdottir I et al (2006) Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 38:320–323CrossRefPubMed Grant SF, Thorleifsson G, Reynisdottir I et al (2006) Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 38:320–323CrossRefPubMed
4.
go back to reference DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium (2014) Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet 46:234–244CrossRef DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium (2014) Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet 46:234–244CrossRef
5.
go back to reference Lyssenko V, Lupi R, Marchetti P et al (2007) Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 117:2155–2163CrossRefPubMedPubMedCentral Lyssenko V, Lupi R, Marchetti P et al (2007) Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 117:2155–2163CrossRefPubMedPubMedCentral
6.
go back to reference Boj SF, van Es JH, Huch M et al (2012) Diabetes risk gene and Wnt effector Tcf7l2/TCF4 controls hepatic response to perinatal and adult metabolic demand. Cell 151:1595–1607CrossRefPubMed Boj SF, van Es JH, Huch M et al (2012) Diabetes risk gene and Wnt effector Tcf7l2/TCF4 controls hepatic response to perinatal and adult metabolic demand. Cell 151:1595–1607CrossRefPubMed
7.
go back to reference Kaminska D, Kuulasmaa T, Venesmaa S et al (2012) Adipose tissue TCF7L2 splicing is regulated by weight loss and associates with glucose and fatty acid metabolism. Diabetes 61:2807–2813CrossRefPubMedPubMedCentral Kaminska D, Kuulasmaa T, Venesmaa S et al (2012) Adipose tissue TCF7L2 splicing is regulated by weight loss and associates with glucose and fatty acid metabolism. Diabetes 61:2807–2813CrossRefPubMedPubMedCentral
8.
go back to reference Yi F, Brubaker PL, Jin T (2005) TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta. J Biol Chem 280:1457–1464CrossRefPubMed Yi F, Brubaker PL, Jin T (2005) TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta. J Biol Chem 280:1457–1464CrossRefPubMed
9.
go back to reference Duval A, Rolland S, Tubacher E, Bui H, Thomas G, Hamelin R (2000) The human T cell transcription factor-4 gene: structure, extensive characterization of alternative splicings, and mutational analysis in colorectal cancer cell lines. Cancer Res 60:3872–3879PubMed Duval A, Rolland S, Tubacher E, Bui H, Thomas G, Hamelin R (2000) The human T cell transcription factor-4 gene: structure, extensive characterization of alternative splicings, and mutational analysis in colorectal cancer cell lines. Cancer Res 60:3872–3879PubMed
10.
go back to reference Korinek V, Barker N, Moerer P et al (1998) Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nat Genet 19:379–383CrossRefPubMed Korinek V, Barker N, Moerer P et al (1998) Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nat Genet 19:379–383CrossRefPubMed
11.
go back to reference Helgason A, Palsson S, Thorleifsson G et al (2007) Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet 39:218–225CrossRefPubMed Helgason A, Palsson S, Thorleifsson G et al (2007) Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet 39:218–225CrossRefPubMed
12.
go back to reference Palmer ND, Hester JM, An SS et al (2011) Resequencing and analysis of variation in the TCF7L2 gene in African Americans suggests that SNP rs7903146 is the causal diabetes susceptibility variant. Diabetes 60:662–668CrossRefPubMedPubMedCentral Palmer ND, Hester JM, An SS et al (2011) Resequencing and analysis of variation in the TCF7L2 gene in African Americans suggests that SNP rs7903146 is the causal diabetes susceptibility variant. Diabetes 60:662–668CrossRefPubMedPubMedCentral
13.
go back to reference Wellcome Trust Case Control C, Maller JB, McVean G et al (2012) Bayesian refinement of association signals for 14 loci in 3 common diseases. Nat Genet 44:1294–1301CrossRef Wellcome Trust Case Control C, Maller JB, McVean G et al (2012) Bayesian refinement of association signals for 14 loci in 3 common diseases. Nat Genet 44:1294–1301CrossRef
15.
go back to reference Hughes JR, Roberts N, McGowan S et al (2014) Analysis of hundreds of cis-regulatory landscapes at high resolution in a single, high-throughput experiment. Nat Genet 46:205–212CrossRefPubMed Hughes JR, Roberts N, McGowan S et al (2014) Analysis of hundreds of cis-regulatory landscapes at high resolution in a single, high-throughput experiment. Nat Genet 46:205–212CrossRefPubMed
16.
go back to reference van de Werken HJ, Landan G, Holwerda SJ et al (2012) Robust 4C-seq data analysis to screen for regulatory DNA interactions. Nat Methods 9:969–972CrossRefPubMed van de Werken HJ, Landan G, Holwerda SJ et al (2012) Robust 4C-seq data analysis to screen for regulatory DNA interactions. Nat Methods 9:969–972CrossRefPubMed
18.
go back to reference Xia Q, Deliard S, Yuan CX, Johnson ME, Grant SF (2015) Characterization of the transcriptional machinery bound across the widely presumed type 2 diabetes causal variant, rs7903146, within TCF7L2. Eur J Hum Genet 23:103–109CrossRefPubMed Xia Q, Deliard S, Yuan CX, Johnson ME, Grant SF (2015) Characterization of the transcriptional machinery bound across the widely presumed type 2 diabetes causal variant, rs7903146, within TCF7L2. Eur J Hum Genet 23:103–109CrossRefPubMed
20.
go back to reference Savic D, Ye H, Aneas I, Park SY, Bell GI, Nobrega MA (2011) Alterations in TCF7L2 expression define its role as a key regulator of glucose metabolism. Genome Res 21:1417–1425CrossRefPubMedPubMedCentral Savic D, Ye H, Aneas I, Park SY, Bell GI, Nobrega MA (2011) Alterations in TCF7L2 expression define its role as a key regulator of glucose metabolism. Genome Res 21:1417–1425CrossRefPubMedPubMedCentral
21.
go back to reference Meller N, Morgan ME, Wong WP, Altemus JB, Sehayek E (2013) Targeting of Acyl-CoA synthetase 5 decreases jejunal fatty acid activation with no effect on dietary long-chain fatty acid absorption. Lipids Health Dis 12:88CrossRefPubMedPubMedCentral Meller N, Morgan ME, Wong WP, Altemus JB, Sehayek E (2013) Targeting of Acyl-CoA synthetase 5 decreases jejunal fatty acid activation with no effect on dietary long-chain fatty acid absorption. Lipids Health Dis 12:88CrossRefPubMedPubMedCentral
22.
go back to reference Bowman T, O’Keeffe K, D’Aquila T et al (2016) CoA synthetase 5 (ACSL5) Ablation in mice increases energy expenditure and insulin sensitivity and delays fat absorption. Mol Metab 5:210–220CrossRefPubMedPubMedCentral Bowman T, O’Keeffe K, D’Aquila T et al (2016) CoA synthetase 5 (ACSL5) Ablation in mice increases energy expenditure and insulin sensitivity and delays fat absorption. Mol Metab 5:210–220CrossRefPubMedPubMedCentral
Metadata
Title
The type 2 diabetes presumed causal variant within TCF7L2 resides in an element that controls the expression of ACSL5
Authors
Qianghua Xia
Alessandra Chesi
Elisabetta Manduchi
Brian T. Johnston
Sumei Lu
Michelle E. Leonard
Ursula W. Parlin
Eric F. Rappaport
Peng Huang
Andrew D. Wells
Gerd A. Blobel
Matthew E. Johnson
Struan F. A. Grant
Publication date
01-11-2016
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 11/2016
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-016-4077-2

Other articles of this Issue 11/2016

Diabetologia 11/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine